Corrigendum to: GPX4 Inhibition Enhances the Antitumor Effect of PARP Inhibitor on Homologous Recombination...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Ovarian cancer remains a significant health challenge, with homologous recombination proficient (HRP) subtypes often exhibiting resistance to standard therapies.
• Poly (ADP-ribose) polymerase (PARP) inhibitors are a targeted therapy for ovarian cancer, but resistance mechanisms limit their efficacy.
• Glutathione peroxidase 4 (GPX4) is implicated in ferroptosis, a regulated cell death pathway, and its role in cancer therapy resistance is under investigation.

Purpose of the Study:

• To investigate the potential of inhibiting GPX4 to enhance the antitumor activity of PARP inhibitors in HRP ovarian cancer cells.
• To explore the synergistic effects of combining GPX4 inhibition with PARP inhibition in preclinical models of ovarian cancer.

Main Methods:

• Utilized cell lines representing HRP ovarian cancer.
• Administered GPX4 inhibitors and PARP inhibitors, both individually and in combination.
• Assessed cell viability, apoptosis, and markers of ferroptosis and DNA damage.

Main Results:

• GPX4 inhibition significantly sensitized HRP ovarian cancer cells to PARP inhibitors.
• Combination therapy resulted in enhanced cell death compared to single-agent treatments.
• Evidence of increased ferroptosis and DNA damage was observed with the combined approach.

Conclusions:

• GPX4 inhibition is a viable strategy to overcome resistance and enhance the efficacy of PARP inhibitors in HRP ovarian cancer.
• The combination of GPX4 and PARP inhibitors represents a promising therapeutic approach for ovarian cancer treatment.